Aug 31, 2022 / 08:30PM GMT
John G. McHutchison - Assembly Biosciences, Inc. - CEO & Director
Good day, everyone. I'm John McHutchison, CEO of Assembly Bio, and I'd like to welcome you to the third and final in our series of planned webcasts for 2022, introducing our expanded research pipeline beyond core inhibitors and hepatitis B.
Bill Delaney, our Chief Scientific Officer, will be talking to you shortly about our 2 newest programs focused on HSV-2 and transplant-associated herpesviruses. And then he and I are honored to have Dr. Michael Houghton join us for the discussion. While I will introduce Dr. Houghton more formally before the Q&A session, Sir Michael needs no introduction. He is a visionary and renowned leader in virology and hepatitis, a Nobel laureate, and we're incredibly fortunate to have him on Assembly Bio's Board of Directors.
As a reminder, we'll be making forward-looking statements, so please refer to our SEC filings for a full list of disclosures.
In 2 short years, Assembly Bio has evolved from being a solely hepatitis B core inhibitor company to a virology company discovering
Assembly Biosciences Inc HSV-2 and Transplant-Associated Herpesviruses Research - Corporate Call Transcript
Sep 01, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers